Ablynx « Terug naar discussie overzicht

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
[verwijderd]
0
[verwijderd]
0
Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
[verwijderd]
0
Op zoek naar overnamekandidaten in de biotech zoals Ablynx of Tigenix.
Conatus pharmaceuticals lijkt een overnameprooi te gaan worden beurskrant.com/2018/03/06/stijgingspo...
3 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
911,91  +1,32  +0,14%  17:54
 Germany40^ 18.735,50 -0,20%
 BEL 20 3.980,58 -0,82%
 Europe50^ 5.076,95 -0,16%
 US30^ 39.519,10 +0,03%
 Nasd100^ 18.206,30 +0,27%
 US500^ 5.225,18 +0,07%
 Japan225^ 38.164,00 -0,07%
 Gold spot 2.335,55 -1,07%
 EUR/USD 1,0795 +0,21%
 WTI 78,84 +0,72%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Air France-KLM +3,99%
Alfen N.V. +3,08%
NX FILTRATION +2,85%
JUST EAT TAKE... +2,08%
PROSUS +2,03%

Dalers

VIVORYON THER... -3,14%
FASTNED -1,71%
BESI -1,39%
SBM Offshore -1,36%
ASML -1,33%